ADXS reported FY3Q17 financials yesterday, and the cash burn was high. Moreover, the start of the phase-1 NEO trial is delayed until 1H18 for undisclosed reasons. The HER2 program has been discontinued.
If all that weren't enough, the company still hasn't named a permanent CEO or explained why the previous CEO was fired.